This article explores the dynamics of BC which, in the end, originates in the deterioration of the blood-borne energy field in conjunction with a wellchronicled nest of hormonal disturbances related to the menstrual cycle. These imbalances, in turn, trigger excessive proliferation of cells in the face of insufficient energy to effect their transformation into functional breast elements. BC is not a disease of cells but of disordered transformation of cells into tissues.
A similar case of metastatic colorectal cancer to ureter and urinary bladder which occurred 3 years after the initial diagnosis and treatment. This was an unexpected finding as no radiological features suggestive
of urothelial tract involvement was identified. However, based on histology, immunohistochemistry and molecular analysis, a diagnosis of metastatic colorectal cancer was made.
Estrogen receptor (ER) positive tumours are more common than ER negative tumours and tend to have a better prognosis. These tumours respond well to endocrine therapy as compared to ER negative tumours, thus avoiding the harmful effects of chemotherapy. Moreover, since ER positive tumours are associated with slow tumour growth and low histology grade, it increases the overall survival.
Everybody is born with the mammary gland. Mammary gland development occurs through various stages throughout embryonic, and stays dormant for males. Although it is uncommon, male also gets breast cancer, occasionally. Male breast cancer accounts for approximately 1% of all breast cancer cases, and it is increasing.
Outcome of most of the biliary and pancreatic malignancy is not good. Demography and involvement of different sites of these malignancies by endoscopic retrograde cholagiopancreatography (ERCP) are not widely studied in Bangladesh.
Primary adenocarcinoma of the duodenum is a rare clinical condition, accounting for only 5% of all gastrointestinal neoplasms and 0.5% of all intestinal neoplasms. Nonspecific clinical presentation contributes to the majority of cases being diagnosed in advanced stages.
The ongoing COVID-19 pandemic has now thrown us into turmoil by adversely affecting the entire socio-economic structure of the world. Currently (Dec 20, 2020), there are 76.4 million incidences worldwide and 17.6 million in the USA, and counting.
The Department of Oncology publishes peer-reviewed; Open Access papers focusing on important advances and their relevance to cancer care. The Department communicates the results of clinical and experimental research within the fields of immunotherapy and chemotherapy. It provides state-of-the-art reviews on clinical and experimental therapies.
The Editors actively encourages Clinical aspects of basic research and trials that will have an impact on the understanding of health and disease. Case reports, focused research on a broad range of disciplines as well as experimental papers may be submitted. Besides, authors may contribute short reviews (by invitation from the Editor) and letters to the editor. This journal adheres to the policies recommended by The Committee on Publication Ethics (COPE).
The following subject areas are covered by Department of Oncology however the accepted papers are not constrained only to the listed areas.
Please direct any enquiry or submit papers to: info@thegms.co